Clinical trials: Influenza Viral Infections, active
Viral Lung Infection and Acute Respiratory Failure
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
- Trial name
- TILIA (NCT05624450)
- Testing
- Tozorakimab
- Where
- 473 sites in United States, Argentina and 37 more
- Volunteers
- 3,527 people
- Sponsor
- AstraZeneca
Respiratory Viral Infections, Influenza
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
The goal of this clinical trial is to evaluate the effects of myxovirus resistance protein A (MxA)-guided antiviral treatment on treatment duration and adverse outcomes in adults hospitalized with influenza or COVID-19, compared…
- Conditions
- Respiratory Viral Infections, Influenza, SARS CoV 2 Infection
- Trial name
- NCT07892872
- Testing
- Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations
- Where
- China
- Volunteers
- 618 people
- Sponsor
- Capital Medical University
Influenza Infection, Infections
Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza
Background: Influenza (flu) is a virus that can infect humans and animals. In humans, the flu can cause mild symptoms such as fever, cough, sore throat, runny nose, muscle aches, headaches, and fatigue.
- Conditions
- Influenza Infection, Infections, Respiratory Virus Infections, Respiratory Tract Infections
- Trial name
- NCT07215871
- Testing
- A/Mallard/Ohio-99/MM4/1989 H10N7
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Syncytial Virus Infections, Immunocompromised Host
RSV, Influenza, and SARS-CoV-2 Outcomes in Severely Immunosuppressed Adults
Respiratory syncytial virus (RSV), influenza, and SARS-CoV-2 are common respiratory viruses. In healthy adults they usually cause mild, cold-like illness, but in people whose immune system is severely weakened - such as people…
- Conditions
- Respiratory Syncytial Virus Infections, Immunocompromised Host, Influenza, COVID - 19
- Trial name
- NCT07816471
- Volunteers
- 350 people
- Sponsor
- Hospital Italiano de Buenos Aires
Influenza, COVID-19
Dime La VerDAD: Verify, Debunk, and Disseminate
Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in…
- Conditions
- Influenza, COVID-19, Communication Research, Health Behavior
- Trial name
- NCT06417762
- Testing
- Science Communication Curriculum Cohort 1, Science communication curriculum Cohort 2, Science communication curriculum Cohort 3
- Where
- 4 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Respiratory Viral Infection
A Clinical Trial Evaluating the Safety and Efficacy of AP1189 Versus Placebo as an add-on to Standard of Care in Participants With Respiratory Insufficiency Expected to be Caused by Infection With Respiratory Viruses
A clinical study to evaluate the efficacy and safety of once daily oral dosing of 100 mg AP1189 or placebo administered for 14 days, as an add-on to standard of care (SOC) in participants with respiratory insufficiency expected…
- Trial name
- RESPIRE (NCT07633288)
- Testing
- AP1189, 100 mg
- Where
- 11 sites in Bosnia and Herzegovina, Montenegro and 2 more
- Volunteers
- 96 people
- Sponsor
- SynAct Pharma Aps
Influenza, Acute Respiratory Viral Infections
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.
This study aims to evaluate the safety and pharmacokinetic profile of the active ingredients Ingavirin forte, capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) relative to single-entity Drug Ingavirin, capsules, 90 mg following…
- Trial name
- NCT07645534
- Testing
- Ingavirin forte, capsules, 90 mg + 20 mg, Ingavirin, capsules, 90 mg
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Upper Respiratory Disease, Influenza
Immune Defense Protein Impact On Respiratory Immune Outcomes
The primary goal of this study is to observe the impact of the IDP® Supplement on the duration and severity of upper respiratory symptoms in older individuals during the cold and flu season.
- Conditions
- Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
- Trial name
- NCT07431840
- Testing
- Immune Defense Protein 50mg Dose, IDP 200mg Dose
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Quantec Ltd
Influenza, Acute Respiratory Viral Infection
Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.
The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product…
- Trial name
- NCT07420985
- Testing
- Ingavirin Forte, 90 mg + 5 mg, Capsules, Ingavirin Forte, 90 mg + 10 mg, Capsules, Ingavirin Forte, 90 mg + 20 mg, Capsules
- Where
- 11 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Valenta Pharm JSC
Angina, Acute Bronchiolitis
Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
Antimicrobial resistance (AMR), considered one of the greatest global threats by the WHO, justifies the development of initiatives to promote appropriate antibiotic use-especially in primary care, where most antibiotics in France…
- Conditions
- Angina, Acute Bronchiolitis, Acute Bronchitis, COPD Exacerbation (AECOPD)
- Trial name
- GRASP (NCT07359287)
- Testing
- Antibiotic prescribing according to guidelines
- Where
- France
- Volunteers
- 4,500 people
- Sponsor
- University Hospital, Caen
Acute Respiratory Infections, Febrile Illnesses
The Fever Clinic Acute Respiratory Cohort
This prospective cohort study aims to characterize the natural progression and outcomes of acute respiratory infections among patients presenting to fever clinics.
- Conditions
- Acute Respiratory Infections, Febrile Illnesses, Community-acquired Pneumonia, Viral Respiratory Tract Infections
- Trial name
- FACTS (NCT07278700)
- Testing
- No intervention involved
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Fudan University
Influenza, Viral Respiratory Infection
Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers
This is a Single Center, First-in-human Study of Safety, Tolerability, and Pharmacokinetic Profile of Ascending Single and Multiple Doses of Ingavirin Forte, Capsules in Healthy Volunteers.
- Trial name
- NCT06859333
- Testing
- Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mg, Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mg, Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Influenza, Human, Influenza, Human Prevention
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza, Human Prevention, Influenza a, Influenza B
- Trial name
- NCT06800950
- Testing
- QIV, QIV Control
- Where
- 3 sites in China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Influenza, Human, Influenza a
Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza a, Influenza Type B, Influenza Viral Infections
- Trial name
- NCT06622590
- Testing
- QIV, QIV control
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences